Back to dashboard
All PlansCoverageMedium impact

DRUG ALERT – Concurrent Use of GLP-1 and DPP-4 Agents

EmblemHealth·Endocrinology, Family Medicine, Internal Medicine +1 more·Pharmacy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

EmblemHealth now discourages concurrent use of GLP-1 and DPP-4 diabetes medications due to lack of clinical benefit. Providers should consider discontinuing DPP-4 inhibitors when patients are on both medication classes.

Action Required

Action needed
Immediately: Clinical staff should review patient medication lists to identify concurrent use of GLP-1 agonists (Victoza, Ozempic, Trulicity, etc.) and DPP-4 inhibitors (Januvia, Tradjenta, Onglyza, etc.). Providers should consider discontinuing DPP-4 inhibitors while continuing GLP-1 agonists. Update medication reconciliation protocols to flag these combinations.

Related policy hubs